Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 8, 2007
JNCI Journal of the National Cancer Institute 2007 99(16):1216-1217; doi:10.1093/jnci/djm126
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/16/1216    most recent
djm126v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twombly, R.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

American Researchers Question Effect of Scandinavian Mammography Debate

Renee Twombly

The first 150 words of the full text of this article appear below.

A public row is taking place among some European investigators over a 22-year-old study that helped lay the foundation for mammography screening worldwide. Some experts question if it could—or even should—affect current practice in the United States.

The dispute centers on the Swedish two-county trial, which reported the largest reduction in breast cancer deaths found in all of the seven randomized mammography screening trials conducted around the world—a 31% decline. Enrolling more than 134,000 women, the 1985 report in The Lancet remains the largest clinical study of the power of mammography to reduce breast cancer deaths, and many say the findings paved the way to- ward mass screenings in many countries. An updated analysis in 1992 by the same group reduced the estimated drop in mortality to 24%, but that benefit is still higher than most other trials have found. "These were powerful findings that helped lead to widespread support . . . [Full Text of this Article]

Does It Matter?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Editor's Note:
J Natl Cancer Inst 2008 100: 156. [Extract] [Full Text] [PDF]